P2RY12 and heart failure: Overall, baseline variables were well balanced among the three subgroups of patients, and the only significant differences observed were: more incidence of previous heart failure in patients not receiving a CD during follow-up, higher hsCRP levels in those receiving a CD in the first three years of follow-up, and fewer patients receiving P2Y12 inhibitors in the group receiving a CD beyond three years of follow-up (Table 1).